The histologic presence of macrophages (tumor-associated macrophages-TAMs) and neutrophils (tumor associated neutrophils-TANs) has been linked to poor clinical outcomes for solid tumors. The exact mechanism for this association with worsened prognosis is unclear. It has been theorized that TAMs are immunomodulated to an alternatively activated state and promote tumor progression. Similarly, TANs have been shown to promote angiogenesis and tumor detachment. TAMs and TANs were characterized for activation state and production of prometastatic mediators in an immunocompetent murine model of pancreatic adenocarcinoma. Specimens from liver metastases were evaluated by immunofluorescence and immunoblotting. TAMS have upregulated expression of CD206 and CD163-markers of alternative activation, (4.14±0.55 fold and 7.36±1.13 fold over control, respectively, p<0.001) but do not have increased expression of classically activated macrophage markers CCR2 and CCR5.
and anti-mouse VEGF:VEGF R2 complex -Gv39M was purchased from East Coast Biologics (New Berwick, ME). Anti-mouse GAPDH was purchased from Cell Signaling 
Immunocompetent murine metastatic model of pancreatic adenocarcinoma.
Experiments were performed on four groups of five C57/BL6 mice (Jackson Laboratories, Bar Harbor, ME), age 8-9 weeks, five mice were used as control. All 
Immunofluorescent Staining (IF).
Tumors from liver specimens with gross metastatic disease, as well as liver specimens from control mice that were not inoculated with Pan02 cells, were examined for the presence of neutrophils, macrophages, and protein markers using IF. Sectioning and staining was performed in 5 µm serial sections of frozen liver segments. Slides were treated in a solution of 30% acetone and 70% methanol for 10 minutes, and dried at room temperature for two minutes. After three washes with phosphate buffer solution (PBS), they were fixed in 4% Paraformaldehyde (PFA). Sections were washed in PBS then blocked with 10% Donkey serum for 30 minutes. They were then incubated overnight at 4°C in primary antibody, anti-mouse neutrophil (Clone 7/4, dilution 1:500 in 1% Bovine Serum Albumin (BSA) in PBS) or anti-mouse macrophage (CD68, dilution 1:500 in 1% BSA), co-stained with one of the following: anti-mouse VEGF:VEGF R2 complex -Gv39M (dilution 1:50 in 1% BSA), OSM (dilution 1:10 in 1% BSA), CD206 (dilution 1:10 in 1% BSA), CD163 (dilution 1:10 in 1%BSA), CCR2 (dilution 1:50 in 1% BSA), CCR5 (dilution 1:50 in 1% BSA), MMP-2 (dilution 1:200 in 1% BSA), or MMP-9 (dilution 1:200 in 1% BSA). . They were then washed in PBS and incubated at room temperature in a dark environment with appropriate secondary antibodies of either a donkey anti-mouse CY3 IgG, donkey anti-goat CY3 IgG, or a donkey anti-rabbit CY3 IgG (all imaged on the red channel), Alexa 488-labeled donkey anti-rat IgG (Molecular Probes, Invitrogen, imaged on the green channel), and bisBenzimide H 33342 trihydrochloride (Sigma-Aldrich, St. Louis, MO, imaged on the blue channel) for 60 minutes. Slides were then washed with PBS, rinsed with distilled water, and air dried. They were mounted with anti-quenching medium and sealed with nail polish. Slides were then examined with a Leica DMRXA digital microscope (Leica Mikroskopie und Syteme, Wetzlar, Germany), and three random pictures from each slide were taken of both areas of tumor as well as the nontumor surrounding liver parenchyma using SlideBook 2.6 software (I.I.I., Denver, CO) at 40X amplification. Neutrophil and macrophage antibody signaling was calculated by SlideBook using the area of the stain signal for neutrophils and macrophages compared to the total area of the image at 40X amplification. Data are presented as mean percentage of masked area ± standard error of the mean. (dilution 1:1000 in 5% BSA), MMP-9 (dilution 1:1000 in 5% BSA), and GAPDH (dilution 1:1000 in 5% BSA). Membranes were then washed with T-PBS and incubated with appropriate horseradish peroxidase labeled secondary antibodies in 5% non-fat dry milk in T-PBS for one hour at room temperature. Protein bands were developed using enhanced chemiluminescence (ECL) technique. Membranes were exposed to Kodak X-Omat film. Densitometry was performed using the NIH software, ImageJ. A density ratio was created by dividing primary band density by density of the GAPDH band for each sample. Data were then normalized to the expression of control liver for each marker from seven experiments run for each antibody, and are presented as the mean fold increases over control liver expression ± standard error of the mean.
Statistical Analysis.
Parametric statistics were used to analyze the data with the assumption of a normal distribution of activation state. Analysis of variance was applied with a Fisher exact, post-hoc examination, p<0.05 was considered significant.
Results:

Hematoxylin and Eosin Staining (H&E)
H&E evaluation of liver metastasis confirmed pancreatic adenocarcinoma, with pleomorphic tumor cells with high nuclear to cytoplasm ratio and heavy hematoxylin staining consistent with typical adenocarcinoma features (Fig. 1 ).
Tumor Microenvironment TAMs and TANs
Immunofluorescence (IF) performed on liver metastases of mice with either anti CD-68 (macrophage) or anti 7/4 (neutrophil) is shown in Figure 2 . In animals that had undergone tumor inoculation, macrophages and neutrophils were found throughout the liver parenchyma in low amounts ( Fig. 2a-b) . However, the amount of each of these inflammatory cells was significantly increased inside the metastases ( Fig. 2c-d) . The masked signal percent of the total area for macrophages was 4.30%±0.55 in the liver parenchyma compared to 9.32%±0.82 in the tumor microenvironment (p<0.001). For neutrophils, the signal was 0.95%±0.12 in the liver parenchyma compared to 5.24%±0.59 in the metastasis (p<0.001). Additionally, the neutrophil infiltration within the tumor microenvironment appeared to be at a higher density along the leading edge (Fig. 2e) . In livers from control mice that were not inoculated with tumor cells, there was a trend toward less macrophage area compared to liver parenchyma from tumorbearing mice, 2.15%±0.26 vs. 4.30%±0.55, respectively (p=0.06). There was also a trend toward decreased neutrophil area in control mouse liver compared to liver parenchyma from tumor-bearing mice, 0.51±0.08 vs. 0.95%±0.12, respectively (p=0.08).
Expression of Alternatively Activated Markers
In evaluating the metastatic tumor microenvironment for the expression of the AAM markers, immunoblotting on homogenates for CD206 and CD163 show low expression of each in control livers, and small but significant increase of expression in the liver parenchyma from livers of tumor bearing mice compared to expression from control livers, 1.40±0.16 fold over control for CD206 (p=0.018), and 2.58±0.37 fold over control for CD163 (p<0.001). Examination of metastases for alternatively activated macrophage markers shows increased expression of CD206 and CD163 compared to control livers and peri-tumor liver parenchyma, 4.14±0.55 fold over control and 7.36±1.13 fold over control, respectively (both p<0.001 vs. control, Fig. 3a-b) . IF staining of the metastatic tumor microenvironment show increased signaling of CD206 ( Fig. 3c-e) and CD163 ( Fig. 3f-h ), and areas of the tumors with increased signaling of each AAM marker co-localized well with areas densely populated with TAMs. Results of staining for these factors in the liver parenchyma from tumor bearing mice showed very little signaling of both CD206 and CD163 (data not shown).
In evaluating the metastatic tumor microenvironment for the expression of the CAM marker CCR2, IF staining showed there was no specific signal in metastases or in the liver parenchyma of tumor bearing mice, and did not co-localize with macrophages (Data not shown). Macrophages co-localizing with CCR2 were not identified in the liver tissue of tumor bearing mice, they were, however, identified in populations of macrophages in the non-tumor splenic parenchyma of the same, tumor bearing mice, which was used as a positive control to confirm antibody function. These results were confirmed by immunoblotting, showing low expression in homogenates of livers of control mice without cancer, liver parenchyma of tumor bearing mice, and slightly decreased expression among the metastases compared to the liver parenchyma.
CCR5 expression within homogenates of liver metastases was decreased 0.32±0.09 fold compared to control (p<0.001, data not shown). Similar to CCR2, specific CCR5 signaling by IF staining was not identified among macrophages in the metastases or in the macrophages in the liver parenchyma from tumor bearing mice (data not shown).
Selective signaling of CCR5 co-localizing with populations of macrophages in non-tumor spleen from the same mice was again used as positive control (Fig. 2g) . In addition, IF staining further showed that neither CAM nor AAM markers co-localized with TANs (data not shown). Figure 4a and 4b show MMP-9 is highly expressed in homogenates from livers with tumors compared to control liver expression, 36.69±6.69 fold over control in the tumor (p<0.001) and 9.90±3.28 fold over control in the surrounding liver parenchyma (p=0.019). In evaluating the tumor microenvironment by IF for MMP-9, focal areas inside the tumor of very high MMP-9 signaling co-localizes to a high degree with TANs ( Fig. 4c-e) . Additionally, high signaling of MMP-9 co-localized with the high density of TANs at the leading edge of the tumor (Fig. 4f) . There does not appear to be any evidence of co-localization of MMP-9 with macrophages within the tumor (Fig. 4g) , or in the peri-tumor liver parenchyma (data not shown).
Evaluation of MMP-9 Co-localization with Tumor-Associated Neutrophils
Metastatic tumor MMP-2 expression among homogenates was also upregulated in a similar manner as MMP-9, 2.53±0.39 fold over control liver expression (p<0.001), but was not increased in the liver parenchyma from tumor bearing mice, 0.95±0.11 fold compared to control (Fig. 4a-b) . However, IF staining of MMP-2 within the tumor microenvironment did not selectively co-localize with either TAMs or TANs (Fig. 4h-i) .
Tumor-Associated Macrophages and Oncostatin M (OSM) and VEGF Colocalization
Immunoblotting of OSM in the homogenates from livers of tumor bearing mice resulted in small but significantly increased expression of OSM compared to control liver expression, 1.51±0.14 fold (p=0.004), and markedly increased expression in the metastases, 3.54±0.39 fold (p<0.001, Fig. 5a-b) . IF staining of OSM and macrophages in the metastatic tumor microenvironment demonstrated co-localization of OSM with TAMs (Fig. 5c) . OSM signal in the tumors did not co-localize well with TANs (Fig. 5d ).
The expression of VEGF is modestly decreased in homogenates of the liver parenchyma of mice with tumors compared to control liver expression, 0.70±0.20 fold compared to control (p=0.14, not significant), and is increased in the metastases 1.88±0.29 fold over control (p=0.006, Fig. 5a-b) . IF staining of VEGF from metastatic tumors showed co-localization with TAMs ( Fig. 5e-g ), with some tumor surface signal as well. VEGF staining within tumors does not reveal co-localization with TANs (Fig. 5h) .
Cumulative results of co-localization studies of TAMs and TANs with markers of activation and growth mediators are summarized in Table 1 .
Discussion:
It is generally believed that the immune system provides surveillance and protection against the development of malignancy, however, several studies have . In our study, we did not observe a relationship between tumor burden and expression of alternative activation. Concomitantly, markers in the CAM-T H 1 paradigm, which would be expected in immunosurveillance, were difficult to detect among macrophages within metastases. In this model, TAMs co-localize with VEGF and OSM, which may be indicative of their role in the production of each factor. TANs appear well equipped to act as effector cells via the production of MMP-9 which has been shown to promote angiogenesis and extracellular matrix degradation. We found TANs, not TAMs, are strongly co-localized with MMP-9, and aggregate along the leading edge of the tumor at the invasive front (Fig. 5f) . These results suggest a polarity of roles between TAMs and TANs, where TAMs appear to supply growth and From a practical standpoint, hepatic metastases are more easily identified and have borders which lend themselves to facile, histologic and IF examination as compared to retroperitoneal metastases. Pancreas cancer progression at non-hepatic locations has a tendency to produce a strong cicatrix reaction making borders difficult to define [32] . It is our expectation that similar and important microenvironmental findings are present in alternate locations, but these are more difficult to study.
Perspectives and Significance:
Although the role of TAMs within the tumor microenvironment has been postulated, this work clearly demonstrates the alternatively activated macrophage paradigm [31] within a metastatic focus of pancreatic carcinoma. We hypothesize that this activation state is driven by the genotypically abnormal tumor cells, which affect the location and function of the metastatic events [18] . Within this paradigm the TAMs play a "managerial" role as they are well equipped to promote the recruitment of effector cells-neutrophils (TANs) that act via matrix metalloproteases at the invasive front of the metastasis to promote further tumor progression. Table 1 
